Methodological issues and therapeutic perspectives in vascular dementia: A review

Archives of Gerontology and Geriatrics

Volumn 33, Issue 1, 2001, Pages 71-80

  Dib, Michel ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SANOFI   (France)

Author keywords

Clinical trials; Diagnosis; Nootropic drugs; Vascular dementia

Indexed keywords

ALPHA TOCOPHEROL; IDEBENONE; NICERGOLINE; NOOTROPIC AGENT; PIRACETAM; POSATIRELIN; PROPENTOFYLLINE;

ALZHEIMER DISEASE; COGNITION; HUMAN; METHODOLOGY; MULTIINFARCT DEMENTIA; NEUROPROTECTION; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION;

EID: 0034912745     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4943(01)00110-8     Document Type: Article

References (62)

1. Apolipoprotein E ε4 allele, temporal lobe atrophy in late-life dementias
2. Résultats hémodynamiques et psychométriques de la nicergoline contre placebo chez des sujets âgés non détériorés
3. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg/day in elderly hypertensive patients with leukoaraiosis
4. Pentoxyfylline in cerebral vascular dementia
5. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomised, controlled trials
6. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers
7. Treatment of acute ischemic stroke with piracetam
8. From neuronal and vascular impairment to dementia
9. Protective effect of adenosine and a novel xanthine-derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus
10. Vascular dementia: challenge of clinical diagnosis
11. Piracetam and platelets: a review of laboratory and clinical data
12. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial
13. Reduction in cerebral ischemic injury in the newborn rat by potentiation of endogenous adenosine
14. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia
15. Re-evaluating the role of vascular changes in the differential diagnosis of Alzheimer's disease and vascular dementia
16. Effects of propentofylline on disorder of learning and memory in rodents
17. Effects of a xanthine derivative, propentofylline, on local cerebral blood flow and glucose utilization in the rat
18. Multi-infarct dementia: a cause of mental deterioration in the elderly
19. Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam
20. A multicenter randomised double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia
21. Prevalence of preexisting dementia in consecutive stroke patients
22. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies
23. New pharmacological aspects in the neurological profile of propentofylline
24. Clinical trials in dementia with propentofylline
25. Classification and diagnosis of vascular dementia
26. Recent advances in dementia research in Japan: Alzheimer-type dementia
27. Ultrastructural study on the effect of an inhibitor of platelet aggregation
28. Neurobehav. disorders
29. Differentiation of vascular dementia from AD on neuropsychological tests
30. A 12-month randomised, placebo-controlled trial of propentofylline (HWA285) in patients with dementia according to DSMIII-R dementia
31. The relationship between apolipoprotein E, dementia and vascular illness
32. Improved cognition after control of risk factors for multi-infarct dementia
33. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials
34. Piracetam: novelty in a unique mode of action
35. Vascular dementia: a contemporary review of epidemiology, diagnosis, prevention and treatment
36. Role of endothelium on alpha-blocking effect of nicergoline on rabbit middle cerebral artery
37. Anti-ischemic effects of propentofylline (HWA 285) against focal cerebral infarction in rats
38. Pathophysiology of vascular dementia and white matter changes
39. Posatirelin in the treatment of vascular dementia: a double-blind multicentre study vs placebo
40. Why are stroke patients prone to develop dementia?
41. The effect of an alpha-blocking agent, nicergoline, on the interaction between blood platelets, elastin and endothelial cells
42. Difficulties in the clinical diagnosis of vascular dementia and dementia of the Alzheimer type-comparison of clinical classifications
43. Vascular dementia: dead or alive?
44. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment
45. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
46. Characterization of risk factors for vascular dementia: the Honolulu-Asia Aging study
47. Propentofylline in the treatment of Alzheimer's disease and vascular dementia; a review of phase III trials
48. Propentofylline (HWA 285) a neuroprotective modulator: Pharmacological profile
49. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study
50. Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain
51. Altered plasma antioxidant status in subjects with Alzheimer disease and vascular dementia
52. Brain infarction and the clinical expression of Alzheimer's disease
53. Neuroprotective effects of nicergoline in immortalized neurons
54. Association of midlife blood pressure to late-life cognitive decline and brain morphology
55. Antioxidant properties of nicergoline; inhibition of brain auto-oxidation and superoxide production of neutrophils in rats
56. Dementia associated with cerebrovascular disease, other degenerative disease and metabolic disorders
57. Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease
58. Inheritance of the ApoE epsilon4 allele increases the rate of brain arophy in dementia patients
59. Vascular dementia: a concise concept?
60. Comparison of diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN)
61. Dementia drug development: use of information systems to harmonize global drug development.